Aetion and the FDA join forces to advance RWE in oncology

Using the Aetion Evidence Platform®, the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence will work with Aetion over 5 years to research new sources of RWD to inform RWE in oncology care.

Aetion, a healthcare analytics company, has announced they are collaborating with the FDA Oncology Center of Excellence over the next 5 years to find and analyze suitable fit-for purpose RWD sources to answer important questions related to cancer prevention, treatment, diagnostics and care. The FDA Oncology Center of Excellence, established in January 2017 following the 21st Century Cures Act of 2016, aims to expedite the review of new medical products in oncology as well as advance the development and regulation of new treatments by leading various research projects and educational programs.

The FDA Oncology Center of Excellence will work with Aetion to leverage RWD gathered through the Aetion Evidence Platform, a software tool for RWD generation and RWE analysis that allows users, such as pharma/biotech, regulators, payers, and health technology assessment bodies, to inform healthcare decision-making, drug development, reimbursement, and policy. Using the Aetion Evidence Platform, both organizations will evaluate real-world outcomes, test causal inference techniques, and address health disparities to promote equity in healthcare.

“We are proud to partner with FDA’s Oncology Center of Excellence to conduct crucial research to advance the use of real-world evidence and to help better serve vulnerable and underrepresented populations,” commented Carolyn Magill, CEO of Aetion. “Our collaboration furthers our mission to understand which treatments work for which patients and brings us closer to achieving health equity among cancer patients.”

During the course of the collaboration, which will run until at least 2027, Aetion and the FDA have committed to making the results and findings of their research available via various dissemination tactics.